The OncLive Gynecologic Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of gynecologic cancers, including ovarian cancer, endometrial cancer, and uterine cancer, among others. This section features news articles, interviews with gynecologic oncologists in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in gynecologic cancers.
Retifanlimab demonstrated encouraging antitumor activity with favorable tolerability in patients with recurrent microsatellite instability–high or mismatch repair deficient endometrial cancer, according to data from the phase 1 POD1UM-101 trial.
Closing out his discussion on the treatment of cervical cancer, Robert L. Coleman, MD, FACOG, FACS, provides thoughts on the optimal sequencing of therapy and importance of clinical trials.
Focusing on novel immune checkpoint inhibitors, Robert L. Coleman, MD, FACOG, FACS, breaks down preclinical and clinical data that support use of balstilimab in patients with advanced cervical cancer.
The European Commission has granted an approval to the combination of pembrolizumab and lenvatinib for the treatment of patients with advanced or recurrent endometrial carcinoma who have disease progression on or following prior platinum-containing therapy in any setting and who are not eligible for curative surgery or radiation.
Several leading experts discussed a variety of tumor types set to influence the next wave of investigative directions and change the standard of care for patients in abstracts at the European Society for Medical Oncology Congress 2021.
Panelists discuss the latest advances in targeting HER2-positive breast cancer, the rapidly evolving landscape of triple-negative breast cancer, the role of maintenance therapy in ovarian cancer, and recent updates in the treatment of patients with endometrial and cervical cancers.
Investigators identified potentially actionable germline variants in 10% of unselected women with newly diagnosed endometrial cancer, supporting the use of upfront multigene panel testing for all in the population.
Panelists reflect on the potential for immune checkpoint inhibition to become a frontline option in metastatic cervical cancer, and what that means for the second-line setting.
An overview of second-line immune checkpoint inhibitor use in patients with relapsed or refractory metastatic cervical cancer.
AGEN1181, a next-generation CTLA-4 inhibitor, exhibited clinical activity both as a monotherapy and in combination with balstilimab in heavily pretreated patients with advanced solid tumors.
Utilizing a multidisciplinary approach to care is critical in the field of ovarian cancer with the substantial advancements that have been made with systemic chemotherapeutic regimens, PARP inhibitors, maintenance therapy, and surgical interventions.
Switching its focus to second-line therapy for metastatic cervical cancer, the panel reviews an unmet need of effective therapy in this setting.
Experts take a closer look at the data points from KEYNOTE-826 to consider pembrolizumab’s potential role in metastatic cervical cancer management.
The addition of a short-term, flat dose of bevacizumab to pembrolizumab was found to enhance the response to anti–PD-1 therapy in the absence of chemotherapy for patients with platinum-resistant epithelial ovarian cancer.
The combination of lenvatinib plus pembrolizumab induced durable responses with a manageable safety profile in adults with previously treated, advanced endometrial cancer, according to a long-term follow-up analysis of a phase 1b/2 study (NCT02501096).
Considerations for the KEYNOTE-826 trial, which tested pembrolizumab in combination with chemotherapy in patients with metastatic cervical cancer.